Jul 10, 2024
Nanoparticle-based delivery system could offer treatment for diabetics with rare insulin allergy
Posted by Saúl Morales Rodriguéz in categories: biotech/medical, health, nanotechnology
Up to 3% of people with diabetes have an allergic reaction to insulin. A team at Forschungszentrum Jülich has now studied a method that could be used to deliver the active substance into the body in a masked form—in the form of tiny nanoparticles.
The insulin is only released in the target organ when the pH value deviates from the slightly alkaline environment in the blood. The molecular transport system could also serve as a platform for releasing other drugs in the body precisely at the target site.
It’s an old dream in pharmacy: To deliver an active ingredient to the exact place in the body where it is most needed—a cancer drug, for example, directly to the tumor tissue. This minimizes its side effects on other organs and ensures that it has its maximum effect at its target.